Enzalutamide (Xtandi®)

Common name: Enzalutamide
Brand name: Xtandi®
 

What is Enzalutamide?

Enzalutamide is an anti-androgen therapy that blocks the action of male hormones and is used to treat metastatic castration-resistant prostate cancer.

Enzalutamide has been approved for the following uses:
  • It is given to men who previously received docetaxel chemotherapy
  • It is also given to men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT)

How is Enzalutamide administered?

Enzalutamide is administered orally as a soft gelatin capsule.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. The table below lists some side effects experienced by those who received enzalutamide. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Back pain
  • Diarrhea
  • Joint pain
  • Headaches
  • Hot flashes
  • Muscle pain
  • Weakness


Is Enzalutamide covered in my province or territory?*

Enzalutamide is covered by provincial drug programs in:
  • Alberta
  • British Columbia
  • New Brunswick
  • Quebec
Enzalutamide is not covered by provincial drug programs in:
  • Manitoba
  • Newfoundland & Labrador
  • Northwest Territories
  • Nova Scotia
  • Nunavut
  • Prince Edward Island
  • Yukon
  • Nunavut
Unknown if enzalutamide is covered by provincial drug programs in:
  • Ontario
  • Saskatchewan

Xtandi Patient Assistance Program

Patient Assistance Programs are offered by pharmaceutical companies to provide medications to those who cannot afford to pay for their medicine.

Please call 1-855-898-2634 for more information and to see if you qualify for this program.

Enzalutamide has been approved for use by Health Canada and has been recommended for funding by the pan-Canadian Oncology Drug Review (pCODR) for both indications.

Read pCODR’s decisions for enzalutamide (xtandi®) below:

Enzalutamide - July 2013

Enzalutamide - June 2015

For more information on pCODR, please visit www.pcodr.ca

*Source: http://drugcoverage.ca/en-ca/search-results.aspx?ID=26297
 
Last Updated: July 2017




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.
More

Prostate Cancer Canada announces new President and CEO

Toronto, December 21, 2017 – After five successful years under the leadership and guidance of outgoing President and CEO, Rocco Rossi, Prostate Cancer Canada (PCC) is excited to announce the appointment of a most worthy successor in Peter Coleridge, past national CEO of the Canadian Mental Health Association and current national President and CEO of Big Brothers Big Sisters of Canada.
More

Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.
More


Click here for news archive